Search Results - type+ii+diabetes

5 Results

Sort By:

Unmet Need: Prevalence of Type 2 Diabetes (T2D) continues to rapidly increase worldwide, contributing significant economic and global health burdens. There is an urgent need for the development of novel therapeutic strategies to treat T2D.Technical Details: Johns Hopkins researchers have identified a novel target to treat T2D and report here the development...

Published: 9/27/2024 | Inventor(s): Dax Fu, Chengfeng Merriman

Keywords(s): Analytical Method, Diabetes, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Metabolic Disorders, Proteomics/Immunoassays, Research Reagent, Target-based Screening Tool, Type II Diabetes

Category(s): Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Research Tools > Assays, Technology Classifications > Therapeutic Modalities > Targets

Highly Specific Monoclonal Antibodies used as Allosteric Inhibitors and Specific Biosensors of Human ZnT8

Unmet NeedType 2 diabetes (T2D) is a growing worldwide public health issue affecting over 500 million people while creating a $1 trillion economic burden on global healthcare economies. Many current and new therapeutics demonstrate varying degrees of effectiveness, but no single agent or combination thereof has been able to provide patients with lasting...

Published: 9/26/2024 | Inventor(s): Dax Fu, Chengfeng Merriman

Keywords(s): Antibodies, Biologics, Diabetes, Discovery/Research Tools, Disease Indication, Metabolic Disorders, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker, Type II Diabetes

Category(s): Technology Classifications > Research Tools > Research Antibodies, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

An ECL-based Autoantibody Assay for Early Diagnosis of T1D Using a Membrane-spanning ZnT8 Antigenic Domain

Unmet NeedApproximately 1.25 million people in the US have type 1 diabetes (T1D) and the rates of newly diagnosed cases in children are on the rise each year. T1D is caused by the development of an autoimmune reaction to pancreatic β cells. The first detectable sign of β cell autoimmunity is the appearance of diabetes-associated autoantibodies, which...

Published: 9/27/2024 | Inventor(s): Dax Fu, Chengfeng Merriman, Liping Yu, Yong Gu

Keywords(s): Assay, Biomarker, Clinical Diagnostics, Diabetes, Diagnostic Biomarker, Diagnostic Tool, Disease Indication, In Vitro Diagnostics (Old), Measurement Tool, Metabolic Disorders, Type II Diabetes

Category(s): Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > In Vivo Diagnostics, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Diagnostics > Diagnostic Biomarkers

Hepatic Kisspeptin Secretion Impairs Insulin Secretion from Pancreatic Bets Cell. Kisspeptin Receptor GPR54 Antagonist for Treatment of Prediabetes and Diabetes Mellitus in Humans.

Unmet NeedGlucagon and insulin work together to keep blood glucose levels balanced. Glucagon stimulates the liver to secrete glucose while insulin suppresses glucose release. If the body does not regulate glucose levels properly, Type 2 diabetes mellitus (T2DM) will develop. Type 2 diabetes mellitus is a world-wide epidemic, projected to affect 1/3...

Published: 9/26/2024 | Inventor(s): Woo-Jin Song, Prosenjit Mondal, Mehboob Hussain

Keywords(s): Biomarker, Diabetes, Disease Indication, Mechanism-of-action Biomarker, Metabolic Disorders, Therapeutic Matter, Therapeutics, Type 2 Diabetes, Type II Diabetes

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Diabetes, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes

Novel Protein Therapeutic for Diabetes and Obesity

Novelty: This technology identifies a novel myonectin protein, which links skeletal muscle to metabolic regulation. Myonectin was found to lower circulating free fatty acid levels by promoting lipid uptake. Value Proposition: Type-2 diabetes, obesity, and metabolic syndrome are diseases that dramatically reduce patient quality of life and lead...

Published: 9/26/2024 | Inventor(s): Marcus Seldin, Guang Wong

Keywords(s): Biomarker, Diabetes, Disease Indication, Mechanism-of-action Biomarker, Metabolic Disorders, Obesity, Therapeutic Matter, Therapeutics, Type II Diabetes

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes